Troublemaking Mutations: Clonal Hematopoiesis for the Prediction of Prognosis in ST-segment Elevation Myocardial Infarction
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Soehnlein O, Libby P
. Targeting inflammation in atherosclerosis - from experimental insights to the clinic. Nat Rev Drug Discov. 2021; 20(8):589-610.
PMC: 8112476.
DOI: 10.1038/s41573-021-00198-1.
View
2.
Pascual-Figal D, Bayes-Genis A, Diez-Diez M, Hernandez-Vicente A, Vazquez-Andres D, de la Barrera J
. Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2021; 77(14):1747-1759.
DOI: 10.1016/j.jacc.2021.02.028.
View
3.
Fuster J, MacLauchlan S, Zuriaga M, Polackal M, Ostriker A, Chakraborty R
. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017; 355(6327):842-847.
PMC: 5542057.
DOI: 10.1126/science.aag1381.
View
4.
Dorsheimer L, Assmus B, Rasper T, Ortmann C, Ecke A, Abou-El-Ardat K
. Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure. JAMA Cardiol. 2018; 4(1):25-33.
PMC: 6439691.
DOI: 10.1001/jamacardio.2018.3965.
View
5.
Wang S, Hu S, Luo X, Bao X, Li J, Liu M
. Prevalence and prognostic significance of DNMT3A- and TET2- clonal haematopoiesis-driver mutations in patients presenting with ST-segment elevation myocardial infarction. EBioMedicine. 2022; 78:103964.
PMC: 8960977.
DOI: 10.1016/j.ebiom.2022.103964.
View